Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

TG Therapeutics (TGTX) stock in plain English

Free brief · no signupStart here
TGTXPublished Nov 13, 2026
TG Therapeutics Inc
Healthcare · Biotechnology
Sells an intravenous antibody treatment for adults with relapsing forms of multiple sclerosis. Develops experimental cell therapies targeting progressive autoimmune diseases.
Assets:
Briumvi productCommercial anti-CD20 intravenous antibody targeting relapsing forms of multiple sclerosis.
Azer-cel programAllogeneic cell therapy candidate under clinical evaluation for progressive multiple sclerosis.
Commercial headquartersMain corporate and operational hub located in Morrisville, North Carolina.
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

63
OPS ScoreOperating finances
Latest quote
-1.88%$64.88
$9.81B
96.4×
$898.03M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 13, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TGTX. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does TG Therapeutics (TGTX) do?

TG Therapeutics Inc (TGTX) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Sells an intravenous antibody treatment for adults with relapsing forms of multiple sclerosis. Develops experimental cell therapies targeting progressive autoimmune diseases. TG Therapeutics sells an antibody therapy for multiple sclerosis that requires short one-hour maintenance infusions. It is worth $9.81B on the market and sold $898.03M over the last year.

Market cap
$9.81B
P/E ratio
96.4×
Annual sales
$898.03M
Sector
Healthcare
Industry
Biotechnology
Brief updated
Nov 13, 2026

Brands and businesses behind TGTX

  • Briumvi: A prescription antibody infusion that generates revenue from sales to treat adults with relapsing multiple sclerosis.

TGTX’s flags, in plain English

Each flag is a number from TG Therapeutics’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 13, 2026.

Stupid Cash

Can pay this year's bills 4.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Wide Gross Margin

Gross margin of 82.7% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Still Climbing

Sales up 426.7% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.

Debt Is Driving

Heavy debt, 132% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more green flags and 2 more risk notes open with the free trial. Try it free for 7 days.

Questions about TGTX

How big is TG Therapeutics?

TG Therapeutics’ market cap is $9.81B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $898.03M: what customers paid the company over the last year, before any costs.

What is TGTX’s P/E ratio?

TGTX’s P/E ratio is 96.4×. Investors pay about 96.4 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with TGTX?

The business relies heavily on revenue generated from a single commercial multiple sclerosis medicine. That is one risk on TG Therapeutics’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From TG Therapeutics’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TGTX’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card